Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report published on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $30.00 price target on the stock. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($1.48) EPS, Q4 2025 earnings at ($1.43) EPS, FY2025 earnings at ($5.71) EPS, Q1 2026 earnings at ($1.48) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($5.67) EPS.

A number of other research firms have also weighed in on NTLA. Oppenheimer decreased their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. BMO Capital Markets decreased their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. Wedbush reaffirmed a “neutral” rating and set a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Citigroup upped their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Stock Up 4.5 %

NASDAQ NTLA opened at $10.35 on Wednesday. The company’s 50 day moving average is $10.61 and its 200-day moving average is $15.19. Intellia Therapeutics has a 12-month low of $8.30 and a 12-month high of $32.00. The firm has a market cap of $1.07 billion, a P/E ratio of -1.90 and a beta of 1.97.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 29,000 shares of company stock valued at $352,551 in the last quarter. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Capstone Investment Advisors LLC boosted its position in Intellia Therapeutics by 1.4% during the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after buying an additional 831 shares during the period. KBC Group NV boosted its position in Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares during the period. Axxcess Wealth Management LLC boosted its position in Intellia Therapeutics by 5.4% during the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock valued at $415,000 after buying an additional 1,044 shares during the period. Ensign Peak Advisors Inc lifted its position in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after purchasing an additional 1,100 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after purchasing an additional 1,538 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.